



13 December 2012  
EMA/678442/2012

## Overview of invented names reviewed in November 2012 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 10 – 13 December 2012

	NRG meeting 24 Jan 2012		NRG meeting 27 March 2012		NRG meeting 29 May 2012		NRG meeting 28 June 2012**		NRG meeting 02 Oct 2012		NRG meeting 20 Nov 2013		2012	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed invented names	74	48	50	49	67	52	-	-	66	51	54	34	<b>311</b>	<b>234</b>
Justification for retention of invented name *	5	1	4	1	0	3	-	-	3	3	-	-	<b>12</b>	<b>8</b>

\*In case of objections to the proposed invented name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMEA website.



	NRG meeting 24 Jan 2012		NRG meeting 27 March 2012		NRG meeting 29 May 2012		NRG meeting 28 June 2012**		NRG meeting 02 Oct 2012		NRG meeting 20 Nov 2012		2012	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Objections														
Total number of objections raised	75	99	91	67	96	75	-	-	83	94	61	61	<b>406</b>	<b>396</b>
<b>Criterion - Safety concerns</b>							-	-						
Similarity with other Invented name	55	79	83	30	91	49	-	-	66	68	46	52	<b>341</b>	<b>278</b>
Conveys misleading therapeutic/pharmaceutical connotations	3	0			0	1	-	-	1	3	4		<b>8</b>	<b>4</b>
Misleading with respect to composition	2	1	1	3	1	5	-	-		3	2		<b>6</b>	<b>12</b>
<b>Criterion - INN concerns</b>							-	-						
Similarity with INN	0	1	1	0	2		-	-	1	7	1	4	<b>5</b>	<b>12</b>
Inclusion of INN stem	2	2	0	5	1	2	-	-		2		4	<b>3</b>	<b>15</b>
<b>Criterion - Other public health concerns</b>							-	-						
Unacceptable qualifiers						5	-	-	3	5	1		<b>4</b>	<b>10</b>
Conveys a promotional message	1	4	0	5	1	1	-	-	4	5	2	1	<b>8</b>	<b>16</b>
Appears offensive or has a bad connotation							-	-	2	1	3		<b>5</b>	<b>1</b>
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	2	0	5	0			-	-			1		<b>8</b>	<b>0</b>
Similarity between name of prodrug and related active substance							-	-					<b>0</b>	<b>0</b>
Others						12	-	-	6		1		<b>7</b>	<b>12</b>

See *Guideline on the Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure (CPMP/328/98 Rev. 5)* for detailed explanations of criteria used.

\*\*Meeting cancelled due to the Olympics